Voyager Therapeutics, Inc. (VYGR)
VYGR Stock Price Chart
Explore Voyager Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VYGR price movements and trends.
VYGR Company Profile
Discover essential business fundamentals and corporate details for Voyager Therapeutics, Inc. (VYGR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2015
Employees
172.00
CEO
Alfred W. Sandrock Jr.
Description
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
VYGR Financial Timeline
Browse a chronological timeline of Voyager Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.55, while revenue estimate is $4.56m.
Earnings released on 7 May 2026
EPS came in at -$0.47 surpassing the estimated -$0.54 by +12.96%, while revenue for the quarter reached $2.59m , missing expectations by -70.49%.
Earnings released on 9 Mar 2026
EPS came in at -$0.46 surpassing the estimated -$0.54 by +14.81%, while revenue for the quarter reached $15.34m , beating expectations by +46.17%.
Earnings released on 10 Nov 2025
EPS came in at -$0.47 surpassing the estimated -$0.53 by +11.32%, while revenue for the quarter reached $13.37m , beating expectations by +27.38%.
Earnings released on 6 Aug 2025
EPS came in at -$0.57 falling short of the estimated -$0.48 by -18.75%, while revenue for the quarter reached $5.20m , missing expectations by -33.83%.
Earnings released on 6 May 2025
EPS came in at -$0.53 falling short of the estimated -$0.35 by -51.43%, while revenue for the quarter reached $6.47m , missing expectations by -53.45%.
Earnings released on 11 Mar 2025
EPS came in at -$0.59 falling short of the estimated -$0.35 by -68.57%, while revenue for the quarter reached $6.28m , missing expectations by -51.51%.
Earnings released on 12 Nov 2024
EPS came in at -$0.16 surpassing the estimated -$0.45 by +64.44%, while revenue for the quarter reached $24.63m , beating expectations by +59.35%.
Earnings released on 6 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.38 by +52.63%, while revenue for the quarter reached $29.58m , beating expectations by +212.66%.
Earnings released on 13 May 2024
EPS came in at -$0.20 surpassing the estimated -$0.44 by +54.55%, while revenue for the quarter reached $19.52m , beating expectations by +107.40%.
Earnings released on 28 Feb 2024
EPS came in at $1.25 surpassing the estimated -$0.29 by +531.03%, while revenue for the quarter reached $90.06m , beating expectations by +336.55%.
Earnings released on 6 Nov 2023
EPS came in at -$0.59 falling short of the estimated -$0.58 by -1.72%, while revenue for the quarter reached $4.61m , missing expectations by -17.01%.
Earnings released on 3 Aug 2023
EPS came in at -$0.51 surpassing the estimated -$0.59 by +13.56%, while revenue for the quarter reached $4.85m , beating expectations by +174.18%.
Earnings released on 9 May 2023
EPS came in at $2.94 surpassing the estimated $0.77 by +281.82%, while revenue for the quarter reached $150.48m , beating expectations by +146.24%.
Earnings released on 7 Mar 2023
EPS came in at -$0.61 falling short of the estimated -$0.57 by -7.02%, while revenue for the quarter reached $41.09m , beating expectations by +880.60%.
Earnings released on 8 Nov 2022
EPS came in at $0.45 surpassing the estimated -$0.32 by +240.63%, while revenue for the quarter reached $41.09m , beating expectations by +336.34%.
Earnings released on 4 Aug 2022
EPS came in at -$0.50 surpassing the estimated -$0.56 by +10.71%, while revenue for the quarter reached $712.00k , missing expectations by -89.87%.
Earnings released on 4 May 2022
EPS came in at -$0.56 falling short of the estimated -$0.14 by -300.00%, while revenue for the quarter reached $658.00k , missing expectations by -94.82%.
Earnings released on 8 Mar 2022
EPS came in at $0.15 surpassing the estimated -$0.32 by +146.87%, while revenue for the quarter reached $28.07m , beating expectations by +553.41%.
Earnings released on 2 Nov 2021
EPS came in at -$0.67 surpassing the estimated -$0.75 by +10.67%, while revenue for the quarter reached $1.48m , missing expectations by -19.46%.
Earnings released on 9 Aug 2021
EPS came in at -$0.80 falling short of the estimated -$0.75 by -6.67%, while revenue for the quarter reached $1.36m , meeting expectations.
VYGR Stock Performance
Access detailed VYGR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
